Antigen reversion of glycogen phosphorylase isoenzyme in carcinoma and proliferative zone of intestinal metaplasia of the human stomach

Shimada, Shinya; Maeno, Masanobu; Misumi, Atsunobu; Takano, Sadamu; Akagi, Masanobu

doi:10.1016/0016-5085(87)90310-6

Cited by 25 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 93.3% (28/30) of the multiple carcinomas and 80.0% (20/25) of the single carcinomas, the biopsy specimens showed positive staining for BGP. The percentage of immunohistochemical positivity for anti-BGP antibody in the intestinal-type carcinoma corresponded well with previous reports [18,19]. Figure 3 shows BGP-IM in a biopsy specimen.…”

Section: Bgp Expression In Endoscopic Biopsy Specimens Of Gastric Carsupporting

confidence: 90%

“…Therefore, the IM significantly correlated with carcinogenesis of intestinal-type cancer should be selected for use as an appropriate marker. Our previous consecutive studies [17][18][19][20][21] revealed that the proportion of BGP positivity in both cancer and IM was significantly greater in the intestinal-type carcinoma than in the diffuse type (P Ͻ 0.001); also, we found that BGP-IM had a much stronger correlation with gastric carcinoma than the conventional type of incomplete-type IM, and BGP-IMs were significantly higher in a proliferating state than in those samples without BGP (P Ͻ 0.05), and p53 mutation occurred only in BGP-IM, suggesting that BGP-IM is a precancerous condition for intestinal-type carcinoma. Thus, our findings indicate that BGP-IM is an excellent marker of the early stage of gastric carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

“…We have previously demonstrated the frequent abnormal expression of brain (fetal)-type glycogen phosphorylase (BGP) in gastric carcinoma, especially in intestinal-type cancer [17][18][19][20][21]. Furthermore, with regard to the carcinogenesis of gastric carcinoma, we have also pointed out the significant role of the generative cells of intestinal metaplasia (IM) expressing BGP (BGP-IM) as a premalignant lesion of intestinal-type adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

BGP expression in gastric biopsies may predict the development of new lesions after local treatment for early gastric cancer

et al. 2002

Self Cite

View full text Add to dashboard Cite

Section: Bgp Expression In Endoscopic Biopsy Specimens Of Gastric Carsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

BGP expression in gastric biopsies may predict the development of new lesions after local treatment for early gastric cancer

et al. 2002

Self Cite

View full text Add to dashboard Cite

“…The physiological role of BGP is poorly understood, but it is generally thought to induce an emergency glucose supply during a stressful and ischaemic period including neoplastic state. In addition, it has been suggested that the major isoform of GP found in fetal and tumour tissues is BGP, and BGP has been demonstrated to be identical with fetal-type GP (Sato et al, 1972;Shimada et al, 1987Shimada et al, , 1999Gelinas et al, 1989).…”

mentioning

confidence: 99%

Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human ‘de novo’ colorectal carcinomas

et al. 2001

View full text Add to dashboard Cite

‘de novo’ carcinogenesis has been advocated besides ‘adenoma carcinoma sequence’ as another dominant pathway leading to colorectal carcinoma. Our recent study has demonstrated that the distribution of brain (fetal)-type glycogen phosphorylase (BGP) positive foci (BGP foci) has a close relationship with the location of ‘de novo’ carcinoma. The aims of the present study are to investigate genetic alteration in the BGP foci and to characterize them in the ‘de novo’ carcinogenesis. 17 colorectal carcinomas without any adenoma component expressing both immunoreactive p53 and BGP protein were selected from 96 resected specimens from our previous study. Further investigations to examine the proliferating cell nuclear antigen (PCNA)-labelling index, and the p53 and the codon 12 of K-ras mutation using the polymerase chain reaction-single strand conformation polymorphism were performed in the BGP foci, BGP negative mucosa and carcinoma. The BGP foci were observed sporadically in the transitional mucosa adjacent to the carcinoma in all cases. The PCNA labelling index in the BGP foci was significantly higher than that in the BGP negative mucosa ( P < 0.001). p53 mutations were observed in 8 carcinomas, but no K-ras mutation was detected. Interestingly, although none of the overexpressions of p53 protein was detected immunohistochemically in the BGP positive foci, the p53 gene frequently (41.2% of the BGP foci tested) mutated in spite of no K-ras mutation. The present study demonstrates potentially premalignant foci in the colorectal transitional mucosa with frequent p53 gene mutation. It is suggested that BGP foci are promising candidates for the further investigation of ‘de novo’ colorectal carcinogenesis. © 2001Cancer Research Campaign http://www.bjcancer.com

show abstract

“…and poorly differentiated adenocarcinoma, respectively, whereas they were rarely observed in glands from patients with peptic ulcers. Moreover, there was an apparent concordance between the locations of well-differentiated adenocarcinomas and the distribution of IM lesions with GP-positive proliferative zones [10].We developed an immunehistochemical method, involving specific antibodies raised against highly purified GP isoforms from rat brain, muscle, and liver tissue, for detecting each GP isoform in human tissues [3], and immunohistochemical staining of the three GP isoforms was performed to identify the types of GP present in well-differentiated adenocarcinoma and in the proliferative zones of IM lesions in the human stomach [11]. Only the FGP isoform was observed in carcinoma cells and the proliferative zones of some IM lesions.…”

mentioning

confidence: 99%

Fetal-type Glycogen Phosphorylase Expression in Intestinal Metaplasia as a Predictor of the Development of Gastric Cancer

Ikeshima¹,

Horino²,

Morinaga³

et al. 2018

Biomark J

Self Cite

View full text Add to dashboard Cite

Glycogen phosphorylase (GP; EC 2.4.1.1) plays a central role in the mobilization of carbohydrate reserves in a wide variety of organs and tissues. There are three major isoforms of mammalian GP; i.e., the muscle, liver, and brain isoforms. The physiological roles of muscle and liver GP are to provide fuel for energy production (to produce the energy required for muscle contraction) and to ensure a constant supply of glucose to extra hepatic tissues, respectively. However, the physiological role of brain GP (BGP) is poorly understood. It has been demonstrated that BGP is the major isoform of GP found in fetal tissue and tumor tissue, and BGP is identical to fetal-type GF (FGP).We have demonstrated that the significant enzymatic activity of FGP in the gastric carcinoma and proliferating cells of particular Intestinal Metaplasia (IM). We studied 136 specimens with gastric carcinoma and the adjacent IM using specific anti-FGP antibody. FGP was expressed in 80% of the intestinal type and 19% of the diffuse type of carcinoma and in 88% and 42% in the generative zone of IM adjacent to each type of cancer foci, respectively. The proportion of the positivity of FGP expression in the cancer and IM was significantly greater in intestinal type carcinoma than in diffuse type. In addition, according to the proliferating cell nuclear antigen labeling index analysis, IM with FGP expression (FGP-IM) were significantly higher in a proliferating state than in IM without FGP, and some of them were co-expressed accumulated p53 in the generative cells. These data indicate that FGP could be one of the fetal biomarkers and FGP-IM could be a premalignant lesion of intestinal type adenocarcinoma.We conducted another study to investigate the incidence of FGP-IM in gastric biopsy specimens and to identify FGP-IM as a predictor of the coexistence of accessory carcinoma and/or metachronous carcinoma. Eight endoscopic biopsy specimens of methylene blue-positive mucosa of the stomach were obtained from the patients with multiple gastric carcinomas (n=14), a single carcinoma (n=25) and atrophic gastritis (n=20), examined the incidence of FGP-IM. FGP positivity was 93.3% in the multiple carcinomas and 80.0% in the single carcinomas. The incidences of FGP-IM in the stomachs with multiple carcinomas, single carcinoma and atrophic gastritis were 83.2 ± 22.8%, 36.5 ± 41.3% and 7.1 ± 18.0%, respectively. The incidence of FGP-IM was significantly higher in the stomachs with multiple carcinomas than in those with a single carcinoma or atrophic gastritis. It is suggested that the frequent appearance of FGP-IM reflects the high potential of carcinogenesis of intestinal type gastric carcinoma and FGP-IM could be a predictive indicator of metachronous gastric carcinoma. Recently, there are increasing opportunities where endoscopic and laparoscopic local treatments are applied for the early gastric carcinoma, therefore, it is significantly important to identify the high-risk group of metachronous recurrence of gastric carcinoma. 2018Vol. and poorly ...

show abstract

Antigen reversion of glycogen phosphorylase isoenzyme in carcinoma and proliferative zone of intestinal metaplasia of the human stomach

Cited by 25 publications

References 22 publications

BGP expression in gastric biopsies may predict the development of new lesions after local treatment for early gastric cancer

BGP expression in gastric biopsies may predict the development of new lesions after local treatment for early gastric cancer

Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human ‘de novo’ colorectal carcinomas

Fetal-type Glycogen Phosphorylase Expression in Intestinal Metaplasia as a Predictor of the Development of Gastric Cancer

Contact Info

Product

Resources

About